Article Details
Retrieved on: 2019-12-27 03:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Pantginis highlighted that near term, PTX-200 in HTR breast cancer should drive Prescient's <b>stock</b> value. "Overall, we believe that PTX-200 may ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here